BTG3 and cancer: For both men and older enrollees, baseline ANA prevalence was lower in those with a history of cancer than in those with no history of cancer (not shown); this suggests the possibility of survival-related length-biased sampling and provides additional evidence of higher mortality for ANA-positive people with cancer in these subgroups.